17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
January 2025 in “Biomedical Reports” Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
9 citations
,
July 2016 in “JAAD case reports” Denosumab treatment for osteoporosis can cause hair loss.
December 2022 in “Jurnal Farmasi Klinik Base Practice” Cyclophosphamide helped 59.4% of children with steroid-resistant nephrotic syndrome but caused side effects in 40.6%.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
1 citations
,
January 2024 in “Skin research and technology” Deoxycholic acid is FDA-approved for reducing submental fat, but its mechanisms are not fully understood.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
20 citations
,
July 2024 in “Archives of Dermatological Research” Dupilumab helps children with alopecia areata regrow hair safely.